Since these initial findings, NF2 has been found to be loss-of-function mutated in ∼20–40% pleural mesothelioma (PM) cases [53–56] and 7% of renal cell carcinoma (RCC) patients [57], with a high degree of subtype-specificity noted, as exemplified by the papillary subtype of RCC, which exhibits a mutation frequency of 23% [58]. Here, NF2 is linked to renal cell carcinoma.